Extended plasma half-life of albumin-binding domain fused human IgA upon pH-dependent albumin engagement of human FcRn in vitro and in vivo
Albumin has a serum half-life of 3 weeks in humans. This feature can be used to improve the pharmacokinetics of shorter-lived biologics. For instance, an albumin-binding domain (ABD) can be used to recruit albumin. A prerequisite for such design is that the ABD-albumin interaction does not interfere...
Saved in:
Main Authors: | Simone Mester (Author), Mitchell Evers (Author), Saskia Meyer (Author), Jeannette Nilsen (Author), Victor Greiff (Author), Inger Sandlie (Author), Jeanette Leusen (Author), Jan Terje Andersen (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2021-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Selection of bispecific antibodies with optimal developability using FcRn‑pH‑HPLC as an optimized FcRn affinity chromatography method
by: Thomas Müller, et al.
Published: (2023) -
Pharmacokinetics of novel Fc-engineered monoclonal and multispecific antibodies in cynomolgus monkeys and humanized FcRn transgenic mouse models
by: Delphine Valente, et al.
Published: (2020) -
Insight into the avidity-affinity relationship of the bivalent, pH-dependent interaction between IgG and FcRn
by: Johannes Reusch, et al.
Published: (2024) -
Efgartigimod, an FcRn antagonist, as a potential treatment for post COVID-19 syndrome
by: Sandra E. Reznik, et al.
Published: (2023) -
The influence of antibody engineering on Fc conformation and Fc receptor binding properties: Analysis of FcRn-binding engineered antibodies and an Fc fusion protein
by: Takuo Suzuki, et al.
Published: (2021)